Affron saffron ingredient receives US patent for mood support


Affron, from Pharmactive Biotech Products, was awarded a U.S. patent for its role in mental wellbeing.


Photo © tsartsianidis

Affron, from Pharmactive Biotech Products (Madrid, Spain), was awarded a U.S. patent for its role in mental wellbeing. Affron contains a high concentration of crocins and safranals—the carotenoid pigments responsible for saffron’s bioactivity, color, and organoleptic qualities.

“This new accreditation marks a momentous milestone for Affron, as it positions it as a leading-edge formulation at the forefront of the U.S. cognitive health category,” said Marguerite Gerritsen, managing director for Pharmactive, in a press release.

Pharmactive has scientifically demonstrated its formulation’s fast-acting capabilities and high bioavailability in a pharmacokinetics study. The ingredient is also supported by six clinical studies demonstrating a positive effect on multiple aspects of mental well-being, including stress relief, improved mood, induced positive feelings, and enhanced sleep quality. It is also the first commercial extract that has clinically demonstrated capacity to raise teens’ spirits.

“Affron’s mood-enhancement capabilities are owed largely to its role in the inhibition of the reuptake of mood-related neurotransmitters, according to the broader spectrum of scientific literature,” said Alberto Espinel, head of strategic R&D in active and functional natural ingredients for Pharmactive, in a press release. “Affron possesses a potent antioxidant and anti-inflammatory impact. This capacity not only balances levels of key neurotransmitters, such as serotonin and dopamine, but also fights the oxidative stress that stress produces in the brain.”

Related Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.